The Role of PET/MRI in Predicting the Outcome of Definitive Chemoradiotherapy for Esophageal Cancer Patients
Investigating the Role of Integrated 18FDG-PET/MRI in Predicting the Treatment Outcome of Definitive Chemoradiotherapy for Patients With Esophageal Cancer
1 other identifier
interventional
22
1 country
1
Brief Summary
PET/MRI has the advantage to assess the metabolism, diffusion, and perfusion parameters of the tumor simultaneously and has been investigated in some cancers with promising results. In this study, we prospectively investigate the role of PET/MRI in evaluating the outcome of patients with esophageal cancer treated by definitive chemoradiotherapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2019
Typical duration for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 13, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
June 30, 2022
CompletedFirst Submitted
Initial submission to the registry
April 28, 2023
CompletedFirst Posted
Study publicly available on registry
May 11, 2023
CompletedMay 11, 2023
April 1, 2023
2.9 years
April 28, 2023
May 9, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Overall survival
Being calculated from the date of diagnosis to the date of death or censor at the date of the last follow- up for surviving patients
3 years
Study Arms (1)
Integrated PET/MRI
EXPERIMENTALThe study patients receive 18F-FDG PET/MRI before and during chemoradiotherapy.
Interventions
The participants receive 18F-FDG PET/MRI before and during definitive chemoradiotherapy.
Eligibility Criteria
You may qualify if:
- Biopsy-proven primary esophageal cancer
- Willing to receive therapy
- The ability to provide written informed consent and receive the scheduled scans
You may not qualify if:
- Woman with pregnancy or during lactation
- A history of other malignancies or concomitant cancers in different anatomical locations
- Not suitable to receive the PET scan such as serum glucose levels of \> 200 mg/dL or space phobia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Linkou Chang Gung Memorial Hospital
Taoyuan District, Taiwan
Related Publications (1)
Chao YK, Chang CB, Chang YC, Chan SC, Chiu CH, Ng SH, Hsieh JC, Wang JH. Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy. Cancer Imaging. 2023 Nov 6;23(1):109. doi: 10.1186/s40644-023-00630-2.
PMID: 37932848DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- STUDY DIRECTOR
Yin-Kai Chao
Chang Gung Memorial Hospital
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NA
- Masking
- NONE
- Purpose
- DIAGNOSTIC
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 28, 2023
First Posted
May 11, 2023
Study Start
August 13, 2019
Primary Completion
June 30, 2022
Study Completion
June 30, 2022
Last Updated
May 11, 2023
Record last verified: 2023-04
Data Sharing
- IPD Sharing
- Will not share